DE602007014389D1 - Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase - Google Patents

Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase

Info

Publication number
DE602007014389D1
DE602007014389D1 DE602007014389T DE602007014389T DE602007014389D1 DE 602007014389 D1 DE602007014389 D1 DE 602007014389D1 DE 602007014389 T DE602007014389 T DE 602007014389T DE 602007014389 T DE602007014389 T DE 602007014389T DE 602007014389 D1 DE602007014389 D1 DE 602007014389D1
Authority
DE
Germany
Prior art keywords
methods
lipoxygenase
constructs
adipocyte
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007014389T
Other languages
English (en)
Inventor
Gary Weisinger
Rona Limor
Naftali Stern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDICAL RES AND INFRASTRUCTURE FUND OF TEL AVIV
Original Assignee
MEDICAL RES AND INFRASTRUCTURE FUND OF TEL AVIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDICAL RES AND INFRASTRUCTURE FUND OF TEL AVIV filed Critical MEDICAL RES AND INFRASTRUCTURE FUND OF TEL AVIV
Publication of DE602007014389D1 publication Critical patent/DE602007014389D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
DE602007014389T 2006-11-01 2007-11-01 Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase Active DE602007014389D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85573606P 2006-11-01 2006-11-01
PCT/IL2007/001333 WO2008053487A2 (en) 2006-11-01 2007-11-01 Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

Publications (1)

Publication Number Publication Date
DE602007014389D1 true DE602007014389D1 (de) 2011-06-16

Family

ID=39251348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007014389T Active DE602007014389D1 (de) 2006-11-01 2007-11-01 Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase

Country Status (7)

Country Link
US (3) US9279127B2 (de)
EP (1) EP2078079B1 (de)
AT (1) ATE508191T1 (de)
CA (1) CA2667971C (de)
DE (1) DE602007014389D1 (de)
IL (1) IL198421A (de)
WO (1) WO2008053487A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601341A (en) 2010-01-22 2014-02-28 Bayer Ip Gmbh Acaricide and/or insecticide active substance combinations
US9265252B2 (en) 2011-08-10 2016-02-23 Bayer Intellectual Property Gmbh Active compound combinations comprising specific tetramic acid derivatives
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2018218185A1 (en) * 2017-05-26 2018-11-29 Marshall University Research Corporation EXPRESSION VECTORS AND RELATED METHODS OF DELIVERY OF Na/K ATPASE/Src RECEPTOR COMPLEX ANTAGONISTS
US20240009249A1 (en) * 2020-11-25 2024-01-11 Flagship Pioneering, Inc. Adipogenic cell compositions and methods

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2507895B2 (ja) * 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
WO1994001549A1 (en) * 1992-07-02 1994-01-20 Sankyo Company, Limited Looped, hairpin ribozyme
US6191169B1 (en) * 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO2003104495A1 (en) 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
WO2003104494A1 (en) 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors
WO2003104477A2 (en) 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH TRANSCRIPTION FACTOR Dp-1 INHIBITORS
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5545729A (en) * 1994-12-22 1996-08-13 Hybridon, Inc. Stabilized ribozyme analogs
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US20050261485A1 (en) 1996-05-23 2005-11-24 Toagosei Co., Ltd., A Japan Corporation Method of producing antisense oligonucleotide
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
EP0856579A1 (de) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US20110003879A1 (en) 2005-03-11 2011-01-06 Vincent Mark D Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
CA2303935A1 (en) * 1997-10-15 1999-04-22 City Of Hope 12(s)-hete receptor blockers
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999059562A2 (en) * 1998-05-20 1999-11-25 City Of Hope Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2362586A1 (en) * 1999-02-12 2000-08-17 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US6110462A (en) * 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
FR2790757B1 (fr) * 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU4671300A (en) * 1999-04-30 2000-11-17 City Of Hope The use of adeno-associated virus (aav) deliver cytoprotective genes
RU2164944C1 (ru) * 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
AU5137901A (en) 2000-04-06 2001-10-23 Coastside Res Method to inhibit lipoxygenase and cancer cell proliferation
PT1407044E (pt) 2000-12-01 2008-01-02 Max Planck Ges Zur Forderung W Moléculas curtas de arn que medeiam a interferência de arn
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
WO2004013313A2 (en) * 2002-03-28 2004-02-12 University Of Florida Antisense nucleic acids
WO2004029070A2 (en) 2002-09-24 2004-04-08 Isis Pharmaceutical, Inc. Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors
WO2004041197A2 (en) 2002-11-01 2004-05-21 Case Western Reserve University Methods of inhibiting glial scar formation
DE60336076D1 (de) * 2002-12-26 2011-03-31 Ono Pharmaceutical Co Adiponectin-promoter und verwendung davon
AU2004217437B2 (en) * 2003-03-05 2009-11-19 Senesco Technologies, Inc. Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
JP4742032B2 (ja) * 2004-03-31 2011-08-10 株式会社東京大学Ｔｌｏ アディポネクチン発現誘導剤およびその利用
US20060078902A1 (en) * 2004-04-15 2006-04-13 Michaeline Bunting Method and compositions for RNA interference
WO2006039285A2 (en) 2004-09-30 2006-04-13 The University Of Georgia Research Foundation, Inc. Compositions and methods for inducing adipose tissue cell death
US7608277B2 (en) 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US20060160110A1 (en) 2004-12-02 2006-07-20 Takayuki Mizutani Methods of designing small interfering RNAs, antisense polynucleotides, and other hybridizing polynucleotides
WO2006130690A2 (en) * 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis

Also Published As

Publication number Publication date
US20170327827A1 (en) 2017-11-16
CA2667971C (en) 2017-04-18
CA2667971A1 (en) 2008-05-08
US9663790B2 (en) 2017-05-30
US20110038923A1 (en) 2011-02-17
ATE508191T1 (de) 2011-05-15
US9279127B2 (en) 2016-03-08
IL198421A (en) 2014-04-30
WO2008053487A2 (en) 2008-05-08
EP2078079B1 (de) 2011-05-04
IL198421A0 (en) 2011-08-01
EP2078079A2 (de) 2009-07-15
WO2008053487A3 (en) 2008-06-19
US20150191734A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
DE602007014389D1 (de) Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ-12-lipoxygenase
PH12019500626A1 (en) Aav treatment of huntington's disease
NZ589230A (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
Matysiak et al. MicroRNA-146a negatively regulates the immunoregulatory activity of bone marrow stem cells by targeting prostaglandin E2 synthase-2
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
EA201290572A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
EP4174179A3 (de) Rna-haltige modifizierte nukleoside und verfahren zur verwendung davon
MX2012012653A (es) Composiciones de dominio de fibronectina estabilizadas, metodos y usos.
EA201290560A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
MY156333A (en) Gene therapy vectors and cytosine deaminases
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
MY163004A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
Shi et al. miR‑486‑5p is upregulated in osteoarthritis and inhibits chondrocyte proliferation and migration by suppressing SMAD2
WO2009136979A3 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
Chowdhury et al. Biomechanical modulation of collagen fragment-induced anabolic and catabolic activities in chondrocyte/agarose constructs
WO2007032794A3 (en) Inhibition of viral gene expression using small interfering rna
EA201171144A1 (ru) ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
MX2022015169A (es) Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
Zhao et al. Neutrophil recruitment mediated by sphingosine 1-phosphate (S1P)/S1P receptors during chronic liver injury
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
Kumar et al. Sequence-specific cleavage of BM2 gene transcript of influenza B virus by 10-23 catalytic motif containing DNA enzymes significantly inhibits viral RNA translation and replication
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
DE602005026834D1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort